Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 2018 is based in LA Palma, California.
Jul 28, 2025, 7:30 AM EDT - 24 days ago
Jul 25, 2025, 8:31 AM EDT - 27 days ago
Jul 24, 2025, 8:31 AM EDT - 4 weeks ago
Jul 22, 2025, 1:30 PM EDT - 4 weeks ago